Siqing Wang

Prof. Siqing Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2016 in Nature Communications
Verified
Journal Article
Open access
YZYinghua Zhao
Yinghua Zhao
XCXiao Chu
Xiao Chu
JCJintong Chen
Jintong Chen
YWYing Wang
Ying Wang
SGSujun Gao
Sujun Gao
SWSiqing Wang
Siqing Wang
Dectin-1 signalling in dendritic cells (DCs) has an important role in triggering protective antifungal Th17 responses. However, whether dectin-1 directs DCs to prime antitumour Th9 cells remains unclear. Here, we show that DCs activated by dectin-1 agonists potently promote naive CD4+ T cells to differentiate into Th9 cells. Abrogation of dectin-1 in DCs completely abolishes their Th9-polarizing capability in response to dectin-1 agonist curdlan. Notably, dectin-1 stimulation of DCs upregulates TNFSF15 and OX40L, which are essential for dectin-1-activated DC-induced Th9 cell priming. Mechanistically, dectin-1 activates Syk, Raf1 and NF-κB signalling pathways, resulting in increased p50 and RelB nuclear translocation and TNFSF15 and OX40L expression. Furthermore, immunization of tumour-bearing mice with dectin-1-activated DCs induces potent antitumour response that depends on Th9 cells and IL-9 induced by dectin-1-activated DCs in vivo. Our results identify dectin-1-activated DCs as a powerful inducer of Th9 cells and antitumour immunity and may have important clinical implications.

19 June 2017 in Leukemia
Verified
Journal Article
Closed access
PDF file
QWQiang Wang
Qiang Wang
YLY Lu
Y Lu
RLR Li
R Li
YJY Jiang
Y Jiang
YZY Zheng
Y Zheng
QYQ Yi
Q Yi

4 February 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YJYuxue Jiang
Yuxue Jiang
JCJintong Chen
Jintong Chen
EBEnguang Bi
Enguang Bi
YZYinghua Zhao
Yinghua Zhao
TQTianxue Qin
Tianxue Qin
SWSiqing Wang
Siqing Wang
Tumor specific Th9 cells are potential effector cells for adoptive therapy of human cancers. TNF family members OX40L, TL1A and GITRL have been shown to promote the induction of Th9 cells and antitumor immunity. However, the role of TNF-α, the prototype of the TNF superfamily cytokines, in Th9 cell differentiation and their antitumor efficacy is not defined. Here, we showed that TNF-α potently promoted naïve CD4+ T cells to differentiate into Th9 cells in vitro. Furthermore, the addition of TNF-α during Th9 cell differentiation increased T cell survival and proliferation. More importantly, the adoptive transfer of TNF-α-treated Th9 cells induced more potent antitumor effects than regular Th9 cells in mouse tumor model. TNF-α signals via two cell surface receptors, TNFR1 and TNFR2. Mechanistic studies revealed that TNF-α drove Th9 cell differentiation through TNFR2 but not TNFR1. In addition, under Th9 polarizing condition, TNF-α activated STAT5 and NF-κB pathways in T cells in a TNFR2-dependent manner. Inhibition of STAT5 and NF-κB pathways by their specific inhibitors impaired TNF-α-induced Th9 cell differentiation. Our results identified TNF-α as a new powerful inducer of Th9 cells and clarified the molecular mechanisms underlying TNF-α-induced Th9 cell differentiation.

31 July 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JCJintong Chen
Jintong Chen
YZYinghua Zhao
Yinghua Zhao
YJYuxue Jiang
Yuxue Jiang
SGSujun Gao
Sujun Gao
YWYiming Wang
Yiming Wang
SWSiqing Wang
Siqing Wang
We recently discovered that dectin-1-activated dendritic cells (DCs) drive potent T helper (Th) 9 cell responses and antitumor immunity. However, the underlying mechanisms need to be further defined. The cytokine microenvironment is critical for Th cell differentiation. Here, we show that dectin-1 activation enhances interleukin (IL)-33 expression in DCs. We found that blocking IL-33/ST2 inhibits dectin-1-activated DC-induced Th9 cell differentiation. More importantly, the addition of IL-33 further promotes Th9 cell priming and antitumor efficacy induced by dectin-1-activated DCs. Mechanistically, in addition to the promotion of Th9 and Th1 cells, dectin-1-activated DCs combined with IL-33 abolish the activity of IL-33 in the induction of regulatory T cells. Furthermore, the combined treatment of dectin-1-activated DCs and IL-33 increases the frequencies of CD4+ T cells by fostering their proliferation and inhibiting their exhaustive differentiation. Thus, our results demonstrate the important role of IL-33 in dectin-1-activated DC-induced Th9 cell differentiation and antitumor efficacy, and suggest that the combination of dectin-1-activated DCs and IL-33 may present a new effective modality of DC-based vaccines in tumor immunotherapy.

1 October 2018 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
NLNing Liu
Ning Liu
YJYuxue Jiang
Yuxue Jiang
JCJintong Chen
Jintong Chen
HNHe Nan
He Nan
YZYinghua Zhao
Yinghua Zhao
SWSiqing Wang
Siqing Wang

8 June 2017 in Oncotarget
Verified
Journal Article
Open access
XZXiaoqing Zhu
Xiaoqing Zhu
YZYinghua Zhao
Yinghua Zhao
YJYuxue Jiang
Yuxue Jiang
TQTianxue Qin
Tianxue Qin
JCJintong Chen
Jintong Chen
SWSiqing Wang
Siqing Wang
Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1 Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1